within Pharmacolibrary.Drugs.ATC.L;

model L04AF07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.991,
    Cl             = 0.06833333333333333,
    adminDuration  = 600,
    adminMass      = 0.006,
    adminCount     = 1,
    Vd             = 0.138,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor used for the treatment of moderate-to-severe plaque psoriasis in adults. It is approved and commercially available in several countries for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult volunteers after single and repeated oral administration.</p><h4>References</h4><ol><li>Ian M Catlett, Urvi Aras, Lars Hansen, Yali Liu, Di Bei, Ihab G Girgis, Bindu Murthy,First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.,Clinical and translational science,2023<a href='https://pubmed.ncbi.nlm.nih.gov/36325947/'>https://pubmed.ncbi.nlm.nih.gov/36325947/</a></li><li>Shan Jing, Yang Lin, Randy Dockens, David Marchisin, Bing He, Ihab G Girgis, Anjaneya Chimalakonda, Bindu Murthy, Urvi Aras,Pharmacokinetics and Safety of the Tyrosine KinaseÂ 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.,Dermatology and therapy,2023<a href='https://pubmed.ncbi.nlm.nih.gov/37981596/'>https://pubmed.ncbi.nlm.nih.gov/37981596/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AF07;
